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Objective. The objective was to compare the safety and cellular immunogenicity of intradermal versus intramuscular
immunization with an HIV-lipopeptide candidate vaccine (LIPO-4) in healthy volunteers. Methodology. A randomized, open-
label trial with 24 weeks of follow-up was conducted in France at six HIV-vaccine trial sites. Sixty-eight healthy 21– to 55–year-
old HIV-uninfected subjects were randomized to receive the LIPO-4 vaccine (four HIV lipopeptides linked to a T-helper–
stimulating epitope of tetanus-toxin protein) at weeks 0, 4 and 12, either intradermally (0.1 ml, 100 mg of each peptide) or
intramuscularly (0.5 ml, 500 mg of each peptide). Comparative safety of both routes was evaluated. CD8
+ T-cell immune
responses to HIV epitopes (ELISpot interferon-c assay) and tetanus toxin-specific CD4
+ T-cell responses (lymphoproliferation)
were assessed at baseline, two weeks after each injection, and at week 24. Results and Conclusion. No severe, serious or life-
threatening adverse events were observed. Local pain was significantly more frequent after intramuscular injection, but local
inflammatory reactions were more frequent after intradermal immunization. At weeks 2, 6, 14 and 24, the respective
cumulative percentages of induced CD8
+ T-cell responses to at least one HIV peptide were 9, 33, 39 and 52 (intradermal group)
or 14, 20, 26 and 37 (intramuscular group), and induced tetanus toxin-specific CD4
+ T-cell responses were 6, 27, 33 and 39
(intradermal), or 9, 46, 54 and 63 (intramuscular). In conclusion, intradermal LIPO-4 immunization was well tolerated, required
one-fifth of the intramuscular dose, and induced similar HIV-specific CD8
+ T-cell responses. Moreover, the immunization route
influenced which antigen-specific T-cells (CD4
+ or CD8
+) were induced. Trial Registration. ClinicalTrials.gov NCT00121121
Citation: Launay O, Durier C, Desaint C, Silbermann B, Jackson A, et al (2007) Cellular Immune Responses Induced with Dose-Sparing Intradermal
Administration of HIV Vaccine to HIV-Uninfected Volunteers in the ANRS VAC16 Trial. PLoS ONE 2(8): e725. doi:10.1371/journal.pone.0000725
INTRODUCTION
One of the greatest challenges in human immunodeficiency virus/
acquired immunodeficiency syndrome (HIV/AIDS) research is to
develop a vaccine that can prevent virus transmission or halt
progression to AIDS. An effective HIV vaccine should induce
neutralizing antibodies to protect against infection [1]. However,
inducing neutralizing antibodies specific to the broad range of
HIV subspecies has proven difficult with current candidate vac-
cines. Alternatively, numerous clinical and experimental observa-
tions have shown that cellular immunity, particularly CD8
+ T
lymphocytes, plays an important role in controlling HIV infection.
These findings led researchers to develop vaccines able to generate
HIV-specific cellular responses. Using HIV peptides covalently
linked to a lipid tail, an epitope-based candidate vaccine was found
to be safe and was able to elicit HIV-specific CD4
+ and CD8
+ T-
cell responses [2]. Lipopeptide formulations successfully induced
antiviral cytotoxic T-lymphocyte (CTL) responses in mice [3–7]
and monkeys [8–10], and hepatitis B virus (HBV)-specific CTL in
humans [11,12]. More recent studies showed that intramuscularly
injected HIV lipopeptides were able to trigger HIV-specific T-cell
responses in HIV-uninfected volunteers [13–15] and HIV-infected
patients [16–17]. The lipid moiety facilitates the peptide’s entry
into antigen-presenting dendritic cells, thereby enhancing cell-
mediated immune responses [18–20].
Intradermal administration is expected to enhance antigen
exposure to antigen-presenting cells, because skin harbors more
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incorporate antigens and migrate to draining lymph nodes to
present antigen fragments to resting T lymphocytes, thereby
initiating antigen-specific immune responses. Thus, the skin is an
attractive site for vaccine delivery, achieving the most effective
immunization with the smallest antigen load. Indeed, studies on
intradermal injection of HBV, rabies and, more recently, influenza
vaccines highlighted the potential of this route in improving
immunogenicity [21–25]. However, most of those studies
evaluated only humoral immune responses; very few examined
whether that route could induce cellular immune responses more
efficiently than intramuscular injection [26]. Moreover, to our
knowledge, no studies have been conducted in humans to
determine whether the immunization route influences the nature
of the antigen-specific CD4
+ or CD8
+ T cell stimulation. Our
preclinical study results showed that intradermal administration of
simian immunodeficiency virus (SIV) lipopeptides triggered
multispecific and sustained SIV-specific T-cell responses in rhesus
macaques [27]. Intradermal injection of HIV lipopeptides might
be used to induce a more favorable immune response. Also,
whether intradermal injection of a fraction of the HIV-lipopeptide
vaccine dose was proven to be as immunogenic as the
intramuscular full dose, it would be a valid dose-sparing strategy.
Encouraged by the results obtained with intradermal lipopeptide
immunization in the SIV–macaque model, we evaluated the safety
and cellular immunogenicity of intradermal injection of one-fifth
the intramuscular dose of the HIV-lipopeptide candidate vaccine
(LIPO-4) [28,29] in a prospective, randomized trial in HIV-
uninfected adult volunteers.
METHODS
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Study design
This multicenter, open-label, randomized, phase I-B trial was
conducted at six HIV-vaccine trial sites in France. The protocol
was reviewed and approved by the Pitie ´–Salpe ˆtrie `re Hospital
Ethics Committee (Paris, France) and all volunteers gave informed
consent.
Participants
HIV-1-uninfected healthy volunteers, 21 through 55 years of age,
were pre-screened according to the procedure established by the
French National Agency for AIDS Research (ANRS) to select
HIV-unexposed healthy volunteers presenting psychological and
sociological stability, i.e. able to be followed and with no plan to
move during the entire trial. The selection procedure consisted in
medical and psychological exams and standard laboratory tests.
Subjects with a pre-existing medical condition or abnormal
laboratory values that could affect the standard or protocol safety
or immunogenicity evaluations were excluded. HIV-negative
status was confirmed by both ELISA and Western blot tests.
A committee composed of physicians specialized in clinical
immunology, internal medicine, infectious diseases, psychiatrists
and a sociologist accepted or not the candidate in the ‘‘ANRS
HIV-uninfected volunteers network’’. They were counseled
regarding the uncertainty of efficacy of the trial vaccine and
the need to avoid HIV infection and they did not receive
financial incentive. Women were required to use effective
contraception and have a negative pregnancy test prior to each
vaccine injection.
Interventions
Subjects were randomized to receive, at weeks 0, 4 and 12, the
LIPO-4 vaccine injected intradermally (0.1 ml) or intramuscularly
(0.5 ml) into the deltoid region of the nondominant arm. Solicited
adverse events included the following local and systemic reactions:
pain, erythema, induration, nodule, vesicle, papule, bulla and/or
edema at the injection site; fever (at least 37.5uC), headache,
malaise, nausea, diarrhea, rash, myalgia and/or arthralgia. Partici-
pants were seen 3 days and 2 weeks after each vaccination for
safety assessment. Vaccination-site induration was measured
3 days postinjection. Information on adverse events was collected
throughout the trial. Adverse events were codified for their
relationship to the study product (none, possibly, probably or
certainly related) and assigned a severity grade. Immune responses
were assessed at weeks 0 (before injection), 2, 6, 14 and 24.
Study Vaccine
LIPO-4 vaccine contains four HIV sequences (Gag77–85, Pol342–
354, Pol476–484 and Nef68–82), covalently linked to a T-helper–
stimulating tetanus toxin (TT) peptide, TT830–843 (Figure 1). To
synthesize these monopalmitoyl peptides, a Boc–Lys–(Fmoc)–OH
group was incorporated at the N-terminal. Next, on-resin
palmitylation was performed as previously described [30], as were
purification, solubilization and formulation (mixed micelles) of the
lipopeptide vaccines [2]. Each lipopeptide was synthesized by
Avecia LifeScience Molecules (Northwich, England) under GMP
conditions, purified to $90%, with identity controlled by amino-
acid–composition analysis after total acid hydrolysis and molecular
mass determination. The final formulation was subjected to
sterilizing filtration under GMP conditions (Sterilyo, Saint-
Amand-les-Eaux, France), and distributed into individual vials,
lyophilized and stored under nitrogen. Each vaccine dose was
a lyophilized mixture of the four lipopeptides that was recon-
stituted with 0.5 ml of a 5% isotonic glucose solution and injected
either intradermally (0.1 ml, 100 mg of each peptide) or in-
tramuscularly (0.5 ml, 500 mg of each peptide).
Objectives
The primary objective was to determine whether intradermal
versus intramuscular LIPO-4 vaccine injection resulted in signifi-
cantly different percentages of participants experiencing any grade
2 or higher adverse event, possibly, probably or certainly related to
the vaccination. Secondary endpoints were the evaluation of T-cell
immune responses.
Outcomes
Safety Assessment. All subjects were observed for 30 minutes
following vaccine administration to check for immediate local
and/or systemic reactions. A self-monitoring diary card was given
to all subjects to record any local and/or systemic reaction
occurring during the post-injection period and any adverse event
occurring during the entire study period. Clinical evaluations were
performed at days 3 and 14 post-injection, where the study staff
reviewed the diary card and followed up on any adverse event that
had occurred since injection. All local and systemic adverse events
were recorded, regardless of severity. The adverse event severity-
grading scale was defined as follows: mild (grade 1) with no
limitation of activities and no medical intervention; moderate
(grade 2) with mild-to-moderate limitation of activities and no or
minimal medical intervention; severe (grade 3) with marked
limitation of activities and medical intervention required; and
potentially life-threatening (grade 4). Local symptoms occurring
at injection-site (e.g., erythema, induration or edema) were
Intradermal HIV Vaccine
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grade 3 for ulceration, superinfection or superficial phlebitis; and
grade 4 for skin necrosis . Physicians graded severity, using self-
monitoring diary cards filled by the volunteer. All events were
coded in MedDRA terms and then linked to MedDRA system-
organ class and preferred terms for reporting. The Events
Validation Committee reviewed all events occurring during the
study for severity and relationship to LIPO-4. Stopping rules were
prespecified for safety concerns, such as grade 3 or 4 adverse
events.
Assessment of Immunogenicity
Long and Short Peptides Short overlapping peptides spanning
the four lipopeptide sequences and known to be optimal CD8
+ T-
lymphocyte–stimulating epitopes were synthesized by NeoMPS
(Strasbourg, France) and tested in ELISpot interferon-c (IFNc)
assays. The compositions of the 12 peptides used are shown in
Figure 1. These sequences cover the range of HLA class-I alleles
expressed by volunteers. The TT peptide (QYIKANSKFI-
GITELKK) known as a helper epitope was used in proliferation
assays.
IFNc Secretion by CD8
+ T Cells Detected by ELISpot
Assay
A one-step stimulation strategy (cultured ELISpot) was used to
amplify the CD8
+ T-cell responses before ELISpot assay [14].
Briefly, 4610
6 fresh peripheral blood mononuclear cells (PBMC)
were incubated for 2 hours at 37uC in complete medium (RPMI-
1640 supplemented with 10% human AB serum) containing
a maximum of six CD8
+ T-cell–stimulating epitopes (2 mgo f
each/ml). PBMC collected before and after each vaccination were
tested for their abilities to secrete IFNc in response to several HLA
class I-restricted peptides. All the HIV-1 epitopes contained in
LIPO-4 were tested independently of the volunteer’s HLA
haplotype. A positive control, including peptides derived from
Epstein-Barr virus (EBV), influenza virus and cytomegalovirus
(CMV) was also used. Positive spots were detected using an AID
ELISpot reader system (AID Autoimmun Diagnostika, Strassberg,
Germany). Negative controls were PBMC incubated in medium
alone. To be assessable, a given cell line had to have one positive
pool of viral peptides (CMV, EBV, influenza virus), or, if none of
the viral peptides generated positive spots for a given subject, the
phytohemagglutinin (PHA; 1 mg/ml; 25,000 cells/well) response
had to be positive. The test of an HIV or viral pool was assessable
when the mean of triplicate wells exceeded 100 spot-forming units
(SFU)/10
6 PBMC. The positive ELISpot threshold was the mean
of triplicate wells three-fold higher than the negative control. The
response to HIV peptides was never the only positive finding.
Peptide-specific T-cell responses were not considered positive if
they were detected before vaccination.
Anti-Tetanus Toxin Peptide-Induced CD4
+ T-Cell
Proliferation
The proliferation of each subject’s fresh PBMC during 7 days of
incubation in complete medium with phytohemagglutinin (PHA;
1 mg/ml), purified protein derivative (1 mg/ml), TT peptide
(1 mg/ml) and staphylococcal enterotoxin B (0.1 mg/ml) was
determined. [
3H]Thymidine uptake was expressed as a stimulation
index: mean test counts/minute (cpm) of quadruplicate wells/
mean background cpm. An index $3 was considered positive.
Due to their structure, lipopeptides are known to induce a CD8
+
T-cell response, although they also elicit a CD4
+ T-cell response
[9,13]. The frequency and duration of the CD8
+ T-cell response
are influenced by the presence of CD4
+ T-cell response. In the
present work, both CD8 (against short HIV peptides) and CD4
(against TT830-843) response were investigated.
Figure 1. Composition of the LIPO-4 vaccine. The amino acid sequences correspond to the four antigenic segments of HIV proteins (red) covalently
linked to the T-helper–stimulating epitope of tetanus toxin (TT, black) and linker residues (green). The lines under the HIV sequences represent 12
previously reported CD8
+ T-cell–stimulating epitopes (peptide numbers in brown); the HLA class-I molecules (A or B in blue) restricting the T-cell
responses are also indicated.
doi:10.1371/journal.pone.0000725.g001
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The null hypothesis was that the intradermal and intramuscular
routes would each have a 45% possibly, probably or certainly
vaccination-related grade 2 or higher adverse event rate, excluding
local pain, i.e., that observed in an ANRS pilot trial using LIPO-4
vaccine (unpublished data). To detect a between-arm difference of
45 versus 80% in a two group continuity corrected chi square test
with 80% power and a two-sided significance level of 0.05, 35
patients per arm suffice.
Randomization—Sequence generation
Randomization was stratified by the participant’s HLA-type, able
to induce CD8 immune responses against 0–1 peptide, 2–5
peptides or 6–11 peptides, respectively. Randomization lists were
generated with a block size of 4 using the statistical program SAS
(SAS system for Windows version 8; SAS, Cary, North Carolina,
United States). The three lists were generated by the trial
statistician, who had no involvement in enrolment, follow-up, or
assessment of participants.
Randomization—Allocation Concealment
Individuals were randomized by computer-generated lists, which
were maintained centrally so no center knew the treatment
allocation of any participant prior to randomization.
Randomization—Implementation
A central coordinating office was responsible for validation of
participant eligibility, randomization, data collection, and moni-
toring. Once the screening process was completed, and in order of
enrolment, each participant was assigned to the intradermal or
intramuscular route by a centralized process, according to
computer-generated random lists. The result of individual
randomization was faxed and e-mailed by the central office to
the trial center.
Blinding
In this open-label study regarding safety assessment, all laboratory
analyses were performed by individuals blinded to administration
route assignments. Clinical staff and volunteers were aware of
route assignments.
Statistical Analysis
The primary outcome was the proportion of subjects experiencing
any grade 2 adverse event possibly, probably or certainly
vaccination-related, injection-site pain excluded (as specified in
the protocol). The proportion including injection-site pain was also
analyzed. CD4
+ T-cell proliferation and CD8
+ T-cell IFNc
secretion were analyzed based on a priori assessable assays at
each time, independently of the vaccination route. Primary and
secondary endpoints were analyzed based on intention-to-treat
(using the same definitions of assessable as for immunological data)
with Fisher’s exact test with small numbers of expected frequencies
(,5) or chi-square test for percentages and 95% exact confidence
intervals, using the statistical program SAS.
RESULTS
Participants
The first enrollment was on 17 August 2004, and the last study
visit was on 28 June 2005. Sixty-eight subjects were enrolled and
randomly assigned to one of the two treatment arms: 33 received
intradermal injections and 35 intramuscular injections (Figure 2).
Their demographic characteristics are given in Table 1. HLA
types, able to induce CD8
+ T-cell responses against 0–1 peptide,
2–5 peptides and 6–11 peptides, were present in 13 (19%), 21
(31%), and 34 (50%) of these subjects, respectively. All 68 subjects,
33 in the intradermal group and 35 in the intramuscular group,
received the first two vaccinations and 44, 22 in each group,
received the third. One volunteer experienced a grade 2 local
symptom after the second intradermal vaccination and did not
Figure 2. ANRS VAC16 Participant flow chart.
doi:10.1371/journal.pone.0000725.g002
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because a severe adverse event occurring in a LIPO-5 vaccine trial
[31]. In this other study, one volunteer developed neurological
symptoms 6 weeks after the second LIPO-5 immunization. The
diagnosis of myelitis was retained. This trial conducted by the NIH
in the United States has been suspended and surveillance of the
volunteers is maintained. This event led the French authorities to
stop all such immunizations temporarily. Although a meta-analysis
of lipopeptide trials conducted during that period concluded that
lipopeptide-vaccine safety was acceptable [29], the interval was too
long to resume LIPO-4 vaccinations and to reach 70 planned
inclusions. Subjects who received 2 vaccinations were followed for
safety assessment and immune responses according to the protocol
until the end of the study and thus, data for all 68 subjects were
available for reactogenicity and immunogenicity analyses.
Safety
No grade-3 or -4 adverse events were reported during the study
(Table 2). Thirty-three (95% confidence interval [CI], 18–52) and
17% (7–34) of intradermally and intramuscularly injected
participants, respectively, experienced a grade 2 adverse event
possibly, probably or certainly vaccination-associated, excluding
injection-site pain (P=0.12). These percentages, without excluding
injection-site pain, were 33 (18–52) and 31 (17–49) for in-
tradermally and intramuscularly injected participants, respectively
(P=0.87). Injection-site pain was significantly less frequent after
intradermal injections (27% (13–45) in intradermal group vs 80%
(63–91) in intramuscular group; P,0.0001), but induration and
pruritus were more common. All resolved without sequelae. In this
small study, incidence of adverse events (grade-2 or higher,
possibly, probably or certainly related, local pain excluded) was
5/24 (21% (7–42)) in subjects who received 2 injections and 12/44
(27% (15–43)) for subjects who received 3 injections; detailed
analysis also revealed that local events were as frequent after the
first, second, and third injections (6% (2–14), 15% (7–25) and 9%
(3–22) of subjects after 1, 2 and 3 injections, respectively) and
systemic reactions were more reported after the first injection
(12% (5–22), 3% (0–10) and 2% (0–12) of subjects after 1, 2 and 3
injections, respectively). Only one intramuscularly injected volun-
teer developed a vaccine-related fever (38.5uC). The frequencies of
Table 1. Demographic characteristics of trial participants as
a function of vaccination route.
......................................................................
Characteristic
Intradermal
(N=33)
Intramuscular
(N=35)
Total
(N=68)
Sex, no. (%)
Male 28 (85) 23 (66) 51 (75)
Female 5 (15) 12 (34) 17 (25)
Age, years, no. (%)
21–30 2 (6) 2 (6) 4 (6)
31–40 9 (27) 7 (20) 16 (24)
41–50 16 (48) 14 (40) 30 (44)
51–55 6 (18) 12 (34) 18 (26)
Median [range] 44 [28–56] 48 [27–56] 47 [27–56]
Vaccinations received, no. (%)
Day 0 33 (100) 35 (100) 68 (100)
Week 4 33 (100) 35 (100) 68 (100)
Week 12 22 (67) 22 (63) 44 (65)
doi:10.1371/journal.pone.0000725.t001
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
Table 2. Frequencies, by maximum severity, of local symptoms
and systemic reactions possibly, probably or certainly related to
vaccination, as a function of immunization route.
........................................................................
Intradermal (N=33) Intramuscular (N=35)
All Reactions
Any 33 (100) 34 (97)
Grade 2
a 11 (33) 11 (31)
Grade 2 (pain excluded)
b 11 (33) 6 (17)
Local Symptoms
Any 33 (100) 32 (91)
Grade 2 8 (24) 7 (20)
Injection-site pain
Any 9 (27) 28 (80)
Grade 2 0 6 (17)
Injection-site erythema
Any 32 (97) 26 (74)
Grade 2 3 (9) 0
Injection-site induration
Any 29 (88) 10 (29)
Grade 2 1 (3) 0
Injection-site pruritus
Any 24 (73) 4 (11)
Grade 2 5 (15) 0
Injection-site edema
Any 4 (12) 4 (11)
Grade 2 1 (3) 1 (3)
Other local symptoms
Any 14 (42) 9 (26)
Grade 2
c 2( 6 ) 0
Systemic Reactions
Any 17 (52) 18 (51)
Grade 2 5 (15) 5 (14)
Myalgia
Grade 1 3 (9) 4 (11)
Headache
Any 3 (9) 4 (11)
Grade 2 0 1 (3)
Nausea
Any 2 (6) 4 (11)
Grade 2 1 (3) 1 (3)
Asthenia
Any 3 (9) 3 (9)
Grade 2 2 (6) 1 (3)
Diarrhea
Any 1 (3) 2 (6)
Grade 2 1 (3) 0
Arthralgia
Grade 1 2 (6) 0
Other systemic symptoms
Any 6 (18) 10 (29)
Grade 2
d 1( 3 ) 3( 9 )
Tabulated values are numbers (percentages) of volunteers experiencing at least
one reaction after any vaccination. Percentages do not add up to 100 because
some volunteers had .1 symptom and/or reaction.
All reactions resolved without sequelae within a median of 56 hours
(interquartile range 9–304 hours).
a95% confidence interval in intradermal (ID) arm:18 to 52% and in intramuscular
(IM) arm: 17 to 49%; ID vs. IM P=0.87.
b95% confidence interval in ID arm:18 to 52% and in IM arm: 7 to 34%; ID vs. IM
P=0.12.
cOther grade-2 local symptoms in the ID arm: local myalgia, injection-site
vesicles.
dOther grade-2 systemic reactions in the IM arm: conjunctivitis, fatigue and
rhinitis; in the intradermal arm: flu-like syndrome.
doi:10.1371/journal.pone.0000725.t002
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ache, nausea, asthenia and diarrhea) were comparable for the two
groups.
Immunogenicity
Induction of HIV-Specific CD8
+ T-Cell Responses Few
responses were seen before vaccination (5 and 2 subjects in
intradermal and intramuscular groups respectively, against 1
peptide in 6 cases, and 2 peptides in 1 case) and in most cases,
these responses were no more detected after vaccination excepted
in one case. Specific cellular responses mounted by PBMC from
17/33 intradermally vaccinated subjects were positive: 11, 3 and 3
generated CD8
+ T cells against one, two or more peptides,
respectively (Figure 3). Thirteen of the 35 intramuscular vaccine
recipients had HIV-specific IFNc secretion by their CD8
+ T cells
generated against one, two or more peptides, for 8, 3 and 2 of
them, respectively. Cumulative percentages (95% CI) of CD8
+ T
cells secreting IFNc in response to at least one HIV peptide were
at weeks 2, 6, 14 and 24, respectively: 9 (2–25), 33 (18–52), 39 (23–
58) and 52 (34–69) for intradermally injected volunteers, and 14
(5–31), 20 (8–37), 26 (12–43) and 37 (21–55), for intramuscularly
injected volunteers. None of the comparisons between routes were
significant at the times tested (P=0.71, 0.21, 0.23, and 0.23 at
weeks 2, 6, 14, and 24, respectively). For subjects who received
three intradermal or intramuscular injections, the respective
cumulative numbers and percentages at weeks 2, 6, 14 and 24
are reported in Figure 4. Thus, intradermal immunization elicited
CD8
+ T-cell responses similar to responses after intramuscular
injections at every time tested.
Ten CD8
+ T-cell–stimulating HIV peptides, among the 12
sequences spanning the vaccine’s four lipopeptides, were recog-
nized by T cells from vaccinated volunteers: peptide 24 by one
intramuscularly vaccinated subject; peptide 13 by six subjects
(three per group); peptides 22, 78 and 87, by twelve subjects (seven
and five subjects from the intradermal and intramuscular arms,
respectively); peptides 29, 64, 65, 66 and 67, by twenty-three
subjects (13 and 10 subjects immunized intradermally and
intramuscularly, respectively).
Lipopeptides TT–Nef and TT–Pol1, which contain several
epitopes unlike lipopeptides TT–Gag and TT–Pol2, were able to
induce most IFNc-secreting CD8
+ T-cell responses. Unsurprising-
ly, HLA-B7 supertype (HLA-B7/-35/-51)-restricted epitopes were
preferentially recognized, reflecting their high representation (5/
12 epitopes) in LIPO-4.
CD4
+ T-Cell Proliferation in Response to Tetanus
Toxin Helper Epitope
Proliferative responses of PBMC from 13/33 (39%; 95% CI, 23–
58) intradermally immunized volunteers were mostly obtained
after at least two LIPO-4 injections (two, seven and four subjects
responded after one, two or three injections, respectively)
(Figure 5). Stimulation indexes ranged from 3 to .10, with nine
subjects having stimulation indexes .5 and six with indexes .10.
Figure 3. CD8
+ T-cell responses (ELISpot IFNc) to HIV peptides as a function of vaccination route, expressed as individual response. Panel A, all
responders (N=68), and Panel B, responders given 3 injections (N=44u. For each responder, the magnitude of the response against individual HIV
peptides, expressed as the total spot-forming units per million peripheral blood mononuclear cells (SFU/10
6 PBMC), evaluated at times 1–4
corresponding to weeks 2, 6, 14 and 24.
doi:10.1371/journal.pone.0000725.g003
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+ T-cells from 22/35
(63%; 95% CI, 45–79) volunteers injected intramuscularly (22/35
for intramuscular versus 13/33 for intradermal group, P=0.053),
with only three responses after a single injection. Thirteen subjects
had stimulation indexes .5. Response intensities, measured by
stimulation indexes (figure 5), did not differ between groups at any
time point. Thus, intramuscular LIPO-4 injection preferentially
elicited CD4
+ T-cell responses to TT epitope.
DISCUSSION
Strategies to improve vaccine immunogenicity include increasing
antigen content and/or the number of immunizations, adding
adjuvant and/or alternative immunization routes. The efficacy of
vaccine delivery to the dermal compartment, one of the body’s
most immunocompetent sites, is probably attributable to contact
between deposited antigen and abundant professional antigen-
presenting cells. Recent results describe lipopeptide penetration
into dendritic cells and, once internalized, their processing via the
cross-presentation pathway into peptides that are presented to
CD8
+ T lymphocytes [20].
Herein, the outcome of intradermal antigen delivery was
evaluated in terms of safety, CD4
+ and CD8
+ T-cell immune
responses, and injection-site reactions after each immunization, in
comparison to classical intramuscular injection. As in previous
clinical trials evaluating HIV lipopeptides [29], our LIPO-4
vaccine was well tolerated. No grade 3 or 4 reactions were
observed. Systemic adverse reactions after vaccination occurred at
similar frequencies in both groups. Local reactions (induration,
pruritus) were more frequent in intradermally vaccinated subjects,
but injection-site pain was more frequent after intramuscular
immunization. Similar findings were obtained in other trials
evaluating intradermal injection [24].
The optimal way to measure antigen-specific T cells remains
a matter of debate, especially since recent observations suggest that
different assays might measure different T-cell responses. Although
the detection of ex vivo IFNc-producing cells using the ELISpot
assay might be useful for identifying immunogenic vaccines, it may
be less informative for the identification of a protective immune
response [32,33]. Previous evaluations of vaccine responses were
based on CTL chromium-release assays using in vitro-enriched T
cells. That approach, by favoring the amplification of dividing T
cells, enabled resting central memory T cells to differentiate into
effector cells. In accordance with that rationale, we, like others
[14,32,34], developed a cultured ELISpot assay using well-defined
CD8
+ T-cell–stimulating epitopes. To examine the kinetics of the
T-cell responses, we assessed immune responses after every LIPO-
4 immunization. The study of cumulative response, which allows
evaluation after each immunization, is a sensitive approach even in
the case of a transient response which could be enhanced after
booster injections [14].
Our findings indicate that HIV-specific T-cell responses were
induced in vaccinated subjects. CD8
+ T-cell IFNc secretion in
response to at least one HIV peptide at weeks 2, 6, 14 and 24,
expressed as cumulative percentages, was, respectively, 9, 33, 39
and 52, for intradermally injected volunteers and 14, 20, 26 and
37, for intramuscularly injected volunteers. In contrast, the
respective percentages of TT peptide-specific CD4
+ T-cell
proliferation were 6, 27, 33 and 39 (intradermal arm) and 9, 46,
54 and 63 (intramuscular arm). To our knowledge, these are the
first data suggesting that the immunization route might affect the
CD4
+ and CD8
+ T-cell phenotypes.
Primary immunization encounters an immune system naive to
the vaccine antigen. When the antigen is readministered in booster
shots, antigen-specific, cellular delayed-type hypersensitivity reac-
tions are triggered. Therefore, we scored skin responses during the
first 72 hours after antigen administration. The nature of skin
responses is not completely understood: no obvious relationship
was observed with lymphocyte proliferation, CD8
+ induction,
delayed hypersensitivity responses and/or intensity or durability of
the skin reactions, as shown figure 5. In terms of response breadth
and in contrast to our results obtained in the SIV–macaque model
using a LIPO-5 formulation injected intradermally, we could not
establish any difference between intradermal and intramuscular
routes concerning immune response induction. This finding
probably indicates that LIPO-4, because it contains only 12
potential epitopes, is not suitable to measuring such parameters.
Intradermal immunization efficacy was reported in human clinical
studies on rabies, hepatitis B and, more recently, influenza [21–
23]. In most of those trials, intradermal injections required less
antigen than intramuscular immunization to elicit an equivalent
antibody response. In the two studies comparing the two routes for
influenza vaccination, intradermal injection with 40 or 20% of the
standard intramuscular dose induced humoral immunogenicity
comparable to that of the full intramuscular dose [24,25]. None of
those studies evaluated T-cell–response induction after intrader-
mal injection. Because of the conflicting data and awaiting new
studies, these vaccines are still intramuscularly administered.
In conclusion, our results demonstrate that intradermally
injected HIV lipopeptides induce complementary CD4
+ and
CD8
+ T-cell responses. Moreover, intradermal injection of 20% of
the intramuscular dose of LIPO-4 vaccine was at least as
Figure 4. CD8
+ T-cell responses (ELISpot IFNc) to HIV peptides as a function of vaccination route, expressed as cumulative percentages. Panel A,
all volunteers (N=68), and Panel B, volunteers who received 3 injections (N=44). The numbers of volunteers who had mounted responses to at least
one HIV peptide at weeks 2, 6, 14, 24 are given above the columns: after intradermal (ID, crosshatched) or intramuscular (IM, empty) injections.
doi:10.1371/journal.pone.0000725.g004
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dose-sparing strategy, although the study was not powered to
demonstrate non-inferiority. However, reduced intramuscular
doses have not yet been evaluated and a study comparing 3 doses
of HIV lipopeptides versus placebo in non-infected volunteers is
currently ongoing (ClinicalTrial.gov identifier: NCT00121758).
Our observations also suggest that combining intradermal and
intramuscular vaccination routes might be a new approach to
improve induction of cellular immunity and warrants further
evaluation.
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